Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension safety study of SD-101 cream in epidermolysis bullosa
MOH_2026-07-06_016922Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- Jul 2026
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nelitolimod in epidermolysis bullosa (EB), sponsored by Takeda. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
nelitolimod
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on MOH_2026-07-06_016922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-07-06_016922.